Developing new antibacterial peptides to fight resistant bacteria
Advancing ribosome-targeting antibacterial peptides with a unique mechanism of action
This study is looking at special proteins from honeybees and fruit flies that can help create new antibiotics to fight tough bacterial infections, which could give patients better treatment options for illnesses caused by bacteria that don't respond to regular medicines.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11044072 on NIH RePORTER |
What this research studies
This research focuses on two antimicrobial peptides, Apidaecin and Drosocin, which are derived from honeybees and fruit flies. These peptides have a unique ability to inhibit bacterial protein synthesis by binding to ribosomes in a way that stops the production of essential proteins in Gram-negative bacteria. The study aims to explore how these peptides can be optimized and screened to create new antibiotics that are effective against resistant bacterial strains. Patients may benefit from new treatment options that can combat infections caused by these difficult-to-treat bacteria.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from infections caused by Gram-negative bacteria, particularly those resistant to current antibiotic treatments.
Not a fit: Patients with infections caused by Gram-positive bacteria or those who do not have bacterial infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel antibiotics that effectively treat infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Other research has shown promise in developing antimicrobial peptides with unique mechanisms, indicating potential for success in this area.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Mankin, Alexander S — University of Illinois at Chicago
- Study coordinator: Mankin, Alexander S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.